Soleno Therapeutics to Participate in the 2021 Cantor Virtual Global Healthcare Conference
Rhea-AI Summary
Soleno Therapeutics, a clinical-stage biopharmaceutical company (NASDAQ: SLNO), announced that CEO Anish Bhatnagar will participate in a fireside chat at the 2021 Cantor Virtual Global Healthcare Conference on September 30, 2021, at 2:40 PM ET.
A live audio webcast and replay can be accessed on the company’s website. Soleno focuses on developing therapeutics for rare diseases, particularly DCCR extended-release tablets for treating Prader-Willi Syndrome, currently in a Phase 3 clinical program.
Positive
- None.
Negative
- None.
News Market Reaction – SLNO
In the trading session that priced this news, SLNO gained 0.75%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
REDWOOD CITY, Calif., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will participate in a fireside chat at the 2021 Cantor Virtual Global Healthcare Conference on Thursday, September 30, 2021 at 2:40 PM Eastern Time.
A live audio webcast and replay of the presentation will be available in the Investors section on the Company’s website at www.soleno.life.
About Soleno Therapeutics, Inc.
Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company’s lead candidate, DCCR extended-release tablets, a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is currently being evaluated in a Phase 3 clinical development program. For more information, please visit www.soleno.life.
Corporate Contact:
Brian Ritchie
LifeSci Advisors, LLC
212-915-2578
